Показаны сообщения с ярлыком antiplatelet. Показать все сообщения
Показаны сообщения с ярлыком antiplatelet. Показать все сообщения

четверг, 22 декабря 2011 г.

Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy

Increased Risk Of Major And Minor Bleeding During Antiplatelet Therapy.


Risk of bleeding for patients on antiplatelet treatment with either warfarin or a bloc of Plavix (clopidogrel) and aspirin is substantial, a rejuvenated inquiry finds. Both therapies are prescribed for millions of Americans to arrest life-threatening blood clots, especially after a nerve bout or stroke Clomid. But the Plavix-aspirin claque was rumination to cause less bleeding than it actually does, the researchers say.



And "As with all drugs, these drugs come with risks; the most bad is bleeding," said govern novelist Dr Nadine Shehab, from the US Centers for Disease Control and Prevention (CDC). While the gamble of bleeding from warfarin is well-known, the risks associated with dual analysis were not well understood, she noted. "We found that the jeopardize for hemorrhage was threefold higher for warfarin than for dual antiplatelet therapy," Shehab said nafodil 25 tab. "We expected that because warfarin is prescribed much more generally than dual antiplatelet therapy".



However, when the researchers took the total of prescriptions into account, the inconsistency between warfarin and dual antiplatelet cure shrank, Shehab said. "And this was worrisome," she added. For both regimens, the include of dispensary admissions because of bleeding was similar. And bleeding-related visits to difficulty bureau visits were only 50 percent debase for those on dual antiplatelet remedy compared with warfarin, Shehab explained. "This isn't as big a change as we had thought," she said.



For the study, published Monday in the Archives of Internal Medicine, Shehab's pair occupied inhabitant databases to name pinch department visits for bleeding caused by either dual antiplatelet group therapy or warfarin between 2006 and 2008. The investigators found 384 annual exigency area visits for bleeding all patients taking dual antiplatelet remedial programme and 2,926 annual visits for those taking warfarin.